Switch to:
Also traded in: Germany, Mexico, Spain, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.24
GIKLY's Cash to Debt is ranked lower than
93% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. GIKLY: 0.24 )
Ranked among companies with meaningful Cash to Debt only.
GIKLY' s Cash to Debt Range Over the Past 10 Years
Min: 0.16  Med: 0.26 Max: 0.32
Current: 0.24
0.16
0.32
Equity to Asset 0.34
GIKLY's Equity to Asset is ranked lower than
84% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. GIKLY: 0.34 )
Ranked among companies with meaningful Equity to Asset only.
GIKLY' s Equity to Asset Range Over the Past 10 Years
Min: 0.3  Med: 0.34 Max: 0.37
Current: 0.34
0.3
0.37
Interest Coverage 3.78
GIKLY's Interest Coverage is ranked lower than
88% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GIKLY: 3.78 )
Ranked among companies with meaningful Interest Coverage only.
GIKLY' s Interest Coverage Range Over the Past 10 Years
Min: 1.56  Med: 4.09 Max: 18.28
Current: 3.78
1.56
18.28
F-Score: 5
Z-Score: 2.28
M-Score: -2.70
WACC vs ROIC
6.02%
12.92%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 24.66
GIKLY's Operating margin (%) is ranked higher than
88% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. GIKLY: 24.66 )
Ranked among companies with meaningful Operating margin (%) only.
GIKLY' s Operating margin (%) Range Over the Past 10 Years
Min: 15.53  Med: 24.81 Max: 26.85
Current: 24.66
15.53
26.85
Net-margin (%) 13.52
GIKLY's Net-margin (%) is ranked higher than
82% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. GIKLY: 13.52 )
Ranked among companies with meaningful Net-margin (%) only.
GIKLY' s Net-margin (%) Range Over the Past 10 Years
Min: 2.8  Med: 12.60 Max: 16.2
Current: 13.52
2.8
16.2
ROE (%) 17.33
GIKLY's ROE (%) is ranked higher than
90% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. GIKLY: 17.33 )
Ranked among companies with meaningful ROE (%) only.
GIKLY' s ROE (%) Range Over the Past 10 Years
Min: 4.27  Med: 17.62 Max: 19.76
Current: 17.33
4.27
19.76
ROA (%) 5.82
GIKLY's ROA (%) is ranked higher than
85% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. GIKLY: 5.82 )
Ranked among companies with meaningful ROA (%) only.
GIKLY' s ROA (%) Range Over the Past 10 Years
Min: 1.34  Med: 5.97 Max: 6.58
Current: 5.82
1.34
6.58
ROC (Joel Greenblatt) (%) 36.87
GIKLY's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. GIKLY: 36.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GIKLY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 17.67  Med: 37.26 Max: 41.3
Current: 36.87
17.67
41.3
Revenue Growth (3Y)(%) 14.50
GIKLY's Revenue Growth (3Y)(%) is ranked higher than
67% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. GIKLY: 14.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GIKLY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 14.5  Med: 22.70 Max: 28.2
Current: 14.5
14.5
28.2
EBITDA Growth (3Y)(%) 12.70
GIKLY's EBITDA Growth (3Y)(%) is ranked higher than
67% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. GIKLY: 12.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GIKLY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 12.7  Med: 32.70 Max: 38.4
Current: 12.7
12.7
38.4
EPS Growth (3Y)(%) 27.40
GIKLY's EPS Growth (3Y)(%) is ranked higher than
81% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. GIKLY: 27.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GIKLY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 7  Med: 29.45 Max: 103
Current: 27.4
7
103
» GIKLY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GIKLY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 24.33
GIKLY's P/E(ttm) is ranked higher than
61% of the 239 Companies
in the Global Biotechnology industry.

( Industry Median: 30.00 vs. GIKLY: 24.33 )
Ranked among companies with meaningful P/E(ttm) only.
GIKLY' s P/E(ttm) Range Over the Past 10 Years
Min: 22.82  Med: 34.39 Max: 96.2
Current: 24.33
22.82
96.2
Forward P/E 14.95
GIKLY's Forward P/E is ranked higher than
60% of the 85 Companies
in the Global Biotechnology industry.

( Industry Median: 17.79 vs. GIKLY: 14.95 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 24.33
GIKLY's PE(NRI) is ranked higher than
62% of the 242 Companies
in the Global Biotechnology industry.

( Industry Median: 30.06 vs. GIKLY: 24.33 )
Ranked among companies with meaningful PE(NRI) only.
GIKLY' s PE(NRI) Range Over the Past 10 Years
Min: 22.65  Med: 33.58 Max: 93.37
Current: 24.33
22.65
93.37
Price/Owner Earnings (ttm) 31.79
GIKLY's Price/Owner Earnings (ttm) is ranked higher than
55% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 36.86 vs. GIKLY: 31.79 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
GIKLY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 18.48  Med: 30.73 Max: 38.16
Current: 31.79
18.48
38.16
P/B 3.94
GIKLY's P/B is ranked lower than
57% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. GIKLY: 3.94 )
Ranked among companies with meaningful P/B only.
GIKLY' s P/B Range Over the Past 10 Years
Min: 2.32  Med: 4.38 Max: 6.76
Current: 3.94
2.32
6.76
P/S 3.31
GIKLY's P/S is ranked higher than
79% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. GIKLY: 3.31 )
Ranked among companies with meaningful P/S only.
GIKLY' s P/S Range Over the Past 10 Years
Min: 1.93  Med: 3.53 Max: 5.09
Current: 3.31
1.93
5.09
PFCF 74.43
GIKLY's PFCF is ranked lower than
77% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 30.80 vs. GIKLY: 74.43 )
Ranked among companies with meaningful PFCF only.
GIKLY' s PFCF Range Over the Past 10 Years
Min: 15.52  Med: 28.87 Max: 87.5
Current: 74.43
15.52
87.5
POCF 17.53
GIKLY's POCF is ranked higher than
63% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. GIKLY: 17.53 )
Ranked among companies with meaningful POCF only.
GIKLY' s POCF Range Over the Past 10 Years
Min: 10.97  Med: 18.15 Max: 2540
Current: 17.53
10.97
2540
EV-to-EBIT 17.53
GIKLY's EV-to-EBIT is ranked higher than
59% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 24.28 vs. GIKLY: 17.53 )
Ranked among companies with meaningful EV-to-EBIT only.
GIKLY' s EV-to-EBIT Range Over the Past 10 Years
Min: 12.6  Med: 19.80 Max: 43.3
Current: 17.53
12.6
43.3
EV-to-EBITDA 14.60
GIKLY's EV-to-EBITDA is ranked higher than
60% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 20.97 vs. GIKLY: 14.60 )
Ranked among companies with meaningful EV-to-EBITDA only.
GIKLY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.3  Med: 16.00 Max: 32.9
Current: 14.6
10.3
32.9
PEG 0.82
GIKLY's PEG is ranked higher than
77% of the 84 Companies
in the Global Biotechnology industry.

( Industry Median: 2.25 vs. GIKLY: 0.82 )
Ranked among companies with meaningful PEG only.
GIKLY' s PEG Range Over the Past 10 Years
Min: 0.66  Med: 0.71 Max: 0.8
Current: 0.82
0.66
0.8
Current Ratio 2.93
GIKLY's Current Ratio is ranked lower than
65% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. GIKLY: 2.93 )
Ranked among companies with meaningful Current Ratio only.
GIKLY' s Current Ratio Range Over the Past 10 Years
Min: 2.7  Med: 2.99 Max: 3.36
Current: 2.93
2.7
3.36
Quick Ratio 1.57
GIKLY's Quick Ratio is ranked lower than
77% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. GIKLY: 1.57 )
Ranked among companies with meaningful Quick Ratio only.
GIKLY' s Quick Ratio Range Over the Past 10 Years
Min: 1.39  Med: 1.58 Max: 1.74
Current: 1.57
1.39
1.74
Days Inventory 244.07
GIKLY's Days Inventory is ranked lower than
80% of the 441 Companies
in the Global Biotechnology industry.

( Industry Median: 121.91 vs. GIKLY: 244.07 )
Ranked among companies with meaningful Days Inventory only.
GIKLY' s Days Inventory Range Over the Past 10 Years
Min: 235.92  Med: 277.48 Max: 348.98
Current: 244.07
235.92
348.98
Days Sales Outstanding 33.61
GIKLY's Days Sales Outstanding is ranked higher than
76% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. GIKLY: 33.61 )
Ranked among companies with meaningful Days Sales Outstanding only.
GIKLY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 33.61  Med: 54.47 Max: 83.07
Current: 33.61
33.61
83.07
Days Payable 74.69
GIKLY's Days Payable is ranked higher than
55% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 64.47 vs. GIKLY: 74.69 )
Ranked among companies with meaningful Days Payable only.
GIKLY' s Days Payable Range Over the Past 10 Years
Min: 64.56  Med: 96.89 Max: 256.52
Current: 74.69
64.56
256.52

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.58
GIKLY's Dividend Yield is ranked higher than
80% of the 206 Companies
in the Global Biotechnology industry.

( Industry Median: 1.33 vs. GIKLY: 1.58 )
Ranked among companies with meaningful Dividend Yield only.
GIKLY' s Dividend Yield Range Over the Past 10 Years
Min: 0.38  Med: 0.74 Max: 1.79
Current: 1.58
0.38
1.79
Dividend Payout 0.41
GIKLY's Dividend Payout is ranked lower than
56% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 0.33 vs. GIKLY: 0.41 )
Ranked among companies with meaningful Dividend Payout only.
GIKLY' s Dividend Payout Range Over the Past 10 Years
Min: 0.2  Med: 0.30 Max: 0.56
Current: 0.41
0.2
0.56
Forward Dividend Yield 1.67
GIKLY's Forward Dividend Yield is ranked higher than
78% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 1.33 vs. GIKLY: 1.67 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.58
GIKLY's Yield on cost (5-Year) is ranked higher than
67% of the 254 Companies
in the Global Biotechnology industry.

( Industry Median: 1.55 vs. GIKLY: 1.58 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
GIKLY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.38  Med: 0.74 Max: 1.79
Current: 1.58
0.38
1.79

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.93
GIKLY's Price/Median PS Value is ranked higher than
52% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. GIKLY: 0.93 )
Ranked among companies with meaningful Price/Median PS Value only.
GIKLY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.59  Med: 0.96 Max: 1.21
Current: 0.93
0.59
1.21
Earnings Yield (Greenblatt) (%) 5.70
GIKLY's Earnings Yield (Greenblatt) (%) is ranked higher than
89% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. GIKLY: 5.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GIKLY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.3  Med: 5.10 Max: 7.9
Current: 5.7
2.3
7.9

More Statistics

Revenue(Mil) $4421
EPS $ 0.44
Beta0.48
Short Percentage of Float0.00%
52-Week Range $9.82 - 12.03
Shares Outstanding(Mil)1367.03

Analyst Estimate

Dec16 Dec17
Revenue(Mil) 4,326 4,531
EPS($) 0.51 0.58
EPS without NRI($) 0.51 0.58

Business Description

Industry: Biotechnology » Biotechnology
Compare:XSWX:RO, OCSE:NOVO B, NAS:GILD, NAS:AMGN, NAS:CELG, NAS:BIIB » details
Traded in other countries:G0FB.Germany, GRFPN.Mexico, GRF.P.Spain, 0RDU.UK, GRFS.USA,
Grifols SA Was incorporated on June 22, 1987. It is a specialty biopharmaceutical company that develops, manufactures and distributes a broad range of plasma derivative products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. The Company operates in four business divisions: Bioscience, Diagnostic, Hospital and Raw Materials and Others. The Bioscience division includes activities relating to the manufacture of plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation and purification of plasma, and the sale and distribution of end products. The main plasma products it manufactures are IVIG, Factor VIII, A1PI and albumin. It also manufactures intramuscular immunoglobulins, ATIII, Factor IX and plasma thromboplastin component, or PTC. The Diagnostic division focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, including analytical instruments and reagents for diagnostics, as well as blood bank products. The Company concentrates its Diagnostic business in immunohematology and hemostasis product lines. The Diagnostic division's main customers are blood donation centers, clinical analysis laboratories and hospital immunohematology services. The Raw Material division provides raw materials for its intravenous therapy products like plastic and glass bottles, which the company purchases from various European suppliers. The Hospital division manufactures and installs products used by and in hospitals, such as parenteral solutions and enteral and parenteral nutritional fluids, which are sold almost exclusively in Spain and Portugal. It also includes products that the company do not manufacture. The Company operates in Latin America, in countries such as Mexico, Colombia, Argentina, Chile and Brazil. It sells Bioscience, Diagnostic and Hospital products to hospitals and clinics, GPOs, governments and other distributors globally. The Company's operations are subject to government authorities in the United States, at the federal, state and local level, and in other countries in which it operates.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK